Worldwide Dendritic Cell Cancer Vaccine Immunotherapy Industry to 2026 - Featuring 3M, Activartis and Argos Therapeutics Among Others

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- The "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to's offering.

Research and Markets Logo
Research and Markets Logo

In the past few years, significant breakthroughs in the medical research have led to the opening of novel doors to harness the immune system of the body against the cancer cells. For the very first time in the history of cancer therapeutics, researchers have discovered a cure that incorporates dendritic cells. The introduction of dendritic cell vaccine immunotherapy into the cancer therapeutics has caused several scientific and medical hurdles to overcome as the opportunities linked with dendritic cells treatment for the cancer patients are huge.

Dendritic cell vaccine immunotherapy among all the immunotherapy treatments is considered as the most potent antigen presenting cells for the proliferation of the T-cells. The uniqueness embedded in the treatment have prompted their applications to be involved in the majority of the treatments as well as wider-acceptance across the globe. The potential of immune system in fighting cancer cells got recognized three-four decades before. Since then, technological and innovative advancement in scientific knowledge has led to the development of novel ally for the cancer patients, which has now become the only hope for declining the cancer mortality rate.

The opening of novel research frontiers with the understanding of biological mechanisms underlying the human cancer and immune system are estimated to be creating promising trends and opportunities for the researchers, patients, physicians and the stakeholders. In addition, some of the factors that are leading to the exponential growth of the market in terms of revenue and size are increasing cancer cases, awareness about the advantages of the dendritic cell vaccine immunotherapy, technology advancement and many more. The dendritic cell vaccine immunotherapy market is catalyzed by a completely and exciting novel range of disruptive technologies required for the re-definition of cancer therapeutics market. In the next few years, researchers are estimated to bring a shift in the treatment paradigm where temporary respite of the cancer treatment will not be boosted in the cancer therapeutic challenge. In the new world, dendritic cell vaccine immunotherapy is estimated to be conquering all the challenges that were challenging to conquer before the arrival of the therapy.

The dendritic cell vaccine immunotherapy market for the cancer patients is estimated to be driven by major three developments advancement in the technology, groundbreaking mechanism of action of the dendritic cells against the cancer cells and consumerization of health through increased access to the patient data provided by artificial intelligence. Unlike, chemotherapy or radiation therapy with which disadvantages are more than advantages, dendritic cell vaccine immunotherapy is estimated to be bursting that bubble. The clinical successes achieved through the therapy has led to the downfall of the hype generated by the old and traditional therapies and eventually boosted the products that are already in the market for the consumption.

The future of the market is estimated to reveal the durability of the clinical responses as well as there will be a significant improvement with respect to broad spectrum development of the market. The downward pressure on the pricing of the developed drugs is estimated to change the upsetting of the market, leading to a great emphasis on the market expansion and acceptance at an international level. Along with these, the market is also observing major players emerging for the overall development of the market.

As per the analysis for Dendritic cell vaccine immunotherapy market, it is estimated that the arrival of the therapy into the market has ended the long-waiting scenario of a therapy capable of efficiently manipulating the dendritic cells and targeting it against the cancer cells. The global healthcare industry for cancer was in an urgent need of such promising therapy where patients could have increased five-year survival rate, minimum side-effects, better targeting ability of the manipulated cells and many more. The unprecedented market drivers are providing a deep insight of the market with respect to the overall progression and its aim to re-define the overall success meter in cancer market as the therapy is tending to perform with high rate of performance.

Report Highlights:

  • Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline

  • Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines

  • Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines

  • Majority Vaccines In Preclinical Phase: More Than 10 Vaccines

  • Global Dendritic Cell Cancer Vaccine Immunotherapy Market Regional Outlook

  • Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase

  • Dosage, Efficacy & Price Insight of Provenge, Apceden & CreaVax

Key Topics Covered:

1. Introduction to Dendritic Cell Cancer Vaccine
1.1 Dendritic Cell Cancer Vaccine Historical Development
1.2 Dendritic Cell Vaccines: A New Era for Cancer Immunotherapy

2. Relevance of Dendritic Cells in Immune System & Cancer Therapy
2.1 Dendritic Cell: Integral Part of Human Immune System
2.2 Effects of Cancer on Dendritic Cell Mediated Immunity

3. Dendritic Cell Cancer Vaccines: Mechanism of Action
3.1 Manufacturing of Dendritic Cell Vaccines
3.2 Mechanism of Dendritic Cell Vaccine against Cancer Cells

4. Dendritic Cell Cancer Vaccine In Combination Therapy
4.1 Radiotherapy
4.2 Monoclonal Antibodies

5. Research & Technological Collaborations for Advancing the Dendritic Cell Immunotherapy Market
5.1 UCLA Researchers Re-Defying Research for Dendritic Cell Immunotherapy
5.2 Personalized Dendritic Cell Vaccine Improving the Overall Survival Rate of Glioblastoma Patients
5.3 Cutting-Edge Grant Approval for Dendritic Cell Immunotherapy Market Advancement in UCLA
5.4 Dendritic Cell Cytokines Leading to Increased Clinical Outcome in Case of Different Cancer Types
5.5 Human Telomerase Reverse Transcriptase (hTERT)-Expressing Autologous Dendritic Cells (hTERT-DCs) Efficiency in Case of Acute Myeloid Leukemia
5.6 APAC Biotech Company to Deliver Dendritic Cell Immunotherapy in India
5.7 Nimbus Therapeutics & Celgene to Work Together for Expanding the Applications of Dendritic Cell Therapy
5.8 Specific Dendritic Cell Vaccines ATTAC Study Result for the Treatment of Glioblastoma
5.9 Bristol Myers Squibb & UbiVac Announces Collaboration for Dendritic Cell-Targeted Microvesicle (DPV-001)
5.10 Cancer Research UK & VOLT to Conduct First-in-Human Trial for Dendritic Cell Therapy
5.11 University of California San Diego Research Work for Confirming the Efficacy of Dendritic Cell Cancer Vaccines
5.12 Interleukin-32 Dendritic Cell Therapy Provoking Promising Strategy Treatment
5.13 Elicio Therapeutics & Moffitt to Evaluate the Combinational Outcomes for AMP-CD19 & CD19 CAR-T Cells
5.14 Dendritic Cell Immunotherapy Discovery as Novel Guards for Immune System
5.15 Non-Small Cell Lung Cancer Treatment by Autologous Dendritic Cancer Cell Vaccines
5.16 Dendritic Cell Immunotherapy Preliminary Reports for Solid & Haematological Malignancies

6. Global Dendritic Cell Cancer Vaccine Immunotherapy Current Market Overview

7. Dendritic Cell Cancer Vaccine Immunotherapy Market Regional Outlook
7.1 North America
7.2 India
7.3 South Korea
7.4 Japan

8. Global Dendritic Cell Cancer Vaccine Immunotherapy Clinical Trials Landscape
8.1 By Phase
8.2 By Patient Segment
8.3 By Company
8.4 By Country
8.5 By Cancer

9. Dendritic Cell Cancer Vaccine Immunotherapy - Dosage, Efficacy & Price Insight
9.1 Provenge
9.2 Apceden (Apceden-L, Apceden-O, Apceden-C, Apceden-P)
9.3 CreaVax RCC

10. Comparative Assessment of Provenge v/s other Therapeutics for Prostate Cancer
10.1 Provenge v/s Jevtana
10.1.1 Clinical Efficacy
10.1.2 Treatment Course & Dosage
10.1.3 Therapy Price Analysis
10.2 Provenge v/s Zytiga
10.2.1 Clinical Efficacy
10.2.2 Treatment Course & Dosage
10.2.3 Therapy Price Analysis

11. Global Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Phase-0
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III

12. Marketed Dendritic Cell Vaccines Immunotherapy Clinical Insight
12.1 CreaVax
12.2 Sipuleucel-T (Provenge)
12.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

13. Promising Future of Dendritic Cell Vaccines in Various Cancer
13.1 Dendritic Cell Vaccine in Stage-III Melanoma
13.2 Dendritic Cell Vaccine in Acute Myeloid Leukemia
13.3 Dendritic Cell Vaccine in Brain Tumor

14. Global Dendritic Cell Cancer Vaccine Market Dynamics
14.1 Favorable Market Parameters
14.2 Market Growth Challenges

15. Global Dendritic Cell Cancer Vaccine Market Future Outlook
15.1 Future Course for Market
15.2 Dendritic Cell Cancer Vaccine Technical Advancements
15.3 Availability of Target Patient Base for Dendritic Cell Cancer Vaccines

16. Competitive Landscape
16.1 3M Company
16.2 Activartis
16.3 Argos Therapeutics
16.4 Batavia Bioservices
16.5 Bellicum Pharmaceuticals
16.6 Creagene
16.7 DanDrit Biotech
16.8 DCPrime
16.9 Dendreon Corporation
16.10 Elios Therapeutics
16.11 ImmunoCellular Therapeutics
16.12 Immunicum
16.13 Kiromic
16.14 Medigene
16.15 Merck
16.16 Northwest Biotherapeutics
16.17 Glaxo Smith Kline
16.18 ImmunoCellular Therapeutics
16.19 SOTIO
16.20 Tella Incorporation
16.21 Theravectys
16.22 Vaxil BioTherapeutics

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


View original content:

SOURCE Research and Markets